What Is Oncotype DX Breast Cancer Test?

The Oncotype DX Breast Cancer Test is a genomic test that examines the activity of a group of 21 genes in a breast cancer tumor. It is primarily used in early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer to help determine the risk of recurrence and whether the patient will benefit from chemotherapy in addition to hormonal therapy.

This test provides a Recurrence Score® (0–100), which guides both patients and oncologists in making informed treatment decisions.

Why Choose Oncotype DX Test In Dubai?

? Genomic Precision: Analyzes tumor biology for personalized risk profiling
? Avoid Unnecessary Chemotherapy: Helps identify if chemotherapy is truly needed
?‍⚕️ Backed By Science: Recommended by top global cancer organizations (ASCO, NCCN)
? Available In Dubai’s Top Oncology Centers
? Recurrence Score® Based Treatment Plan
? Results In 10–14 Days

Who Should Take The Oncotype DX Test?

✔️ Women recently diagnosed with early-stage (I or II) HR+/HER2- breast cancer
✔️ Tumor size up to 5 cm and no spread to distant organs
✔️ Lymph node-negative or up to 3 positive nodes
✔️ Post-surgical patients evaluating treatment options
✔️ Anyone looking to avoid overtreatment with chemotherapy

Benefits Of The Oncotype DX Breast Cancer Test

✨ Tailored Treatment Plan
✨ Avoid Over-Treatment (chemotherapy when it’s not needed)
✨ Higher Confidence In Medical Decision-Making
✨ Non-Invasive – Requires Only A Tumor Sample
✨ Improved Quality Of Life Through Personalized Care

Procedure Of The Test

1. Tumor Sample Collection

   • A formalin-fixed, paraffin-embedded (FFPE) tissue sample is collected after a biopsy or surgery.

2. Sample Sent To Specialized Lab

   • The sample is shipped to the centralized Genomic Health laboratory.

3. Gene Expression Testing

   • A panel of 21 genes is analyzed using advanced RT-PCR (Reverse Transcription Polymerase Chain Reaction) techniques.

4. Report With Recurrence Score®

   • You receive a personalized report with a score between 0 and 100, indicating your risk of recurrence and potential chemotherapy benefit.

Methodology Of The Test

The Oncotype DX Breast Cancer Test uses RT-PCR (Reverse Transcription Polymerase Chain Reaction) to measure the expression levels of 16 cancer-related genes and 5 reference genes from the tumor tissue.

? The 21-gene panel includes genes associated with:

• Proliferation

• Invasion

• Hormonal response

• HER2 expression

? The test generates a Recurrence Score (RS):

• 0–25: Lower risk → may avoid chemotherapy

• 26–100: Higher risk → chemotherapy may be beneficial

This method ensures high sensitivity, reproducibility, and clinical relevance in guiding breast cancer treatment decisions.

Conclusion

The Oncotype DX Breast Cancer Test is a revolutionary tool in the field of personalized oncology. It empowers women and their doctors in Dubai with genomic insights to make the most informed choices about treatment, especially when deciding on chemotherapy.

? With its ability to reduce unnecessary treatments and side effects, the test is an investment in precision care, emotional relief, and overall well-being.
?If you or a loved one has been diagnosed with early-stage HR+ breast cancer in Dubai, consider the Oncotype DX Test to guide the next steps with clarity and confidence. ?